The genetic origin of evolidine, the first cyclopeptide discovered in plants, and related orbitides by Fisher, Mark F. et al.
The genetic origin of evolidine, the first cyclopeptide
discovered in plants, and related orbitides
Received for publication, June 12, 2020, and in revised form, August 11, 2020 Published, Papers in Press, August 19, 2020, DOI 10.1074/jbc.RA120.014781
Mark F. Fisher1 , Colton D. Payne2, Thaveshini Chetty1, Darren Crayn3 , Oliver Berkowitz4 , James Whelan4,
K. Johan Rosengren2 , and Joshua S. Mylne1,*
From the 1University of Western Australia, School of Molecular Sciences & The ARC Centre of Excellence in Plant Energy Biology,
Crawley, Western Australia, Australia, the 2University of Queensland, Faculty of Medicine, School of Biomedical Sciences,
Brisbane, Queensland, Australia, the 3Australian Tropical Herbarium, James Cook University, Cairns, Queensland, Australia, and
the 4Department of Animal, Plant and Soil Sciences, School of Life Sciences & ARC Centre of Excellence in Plant Energy Biology,
AgriBio, The Centre for AgriBioscience, La Trobe University, Bundoora, Victoria, Australia
Edited by Joseph M. Jez
Cyclic peptides are reported to have antibacterial, antifungal,
and other bioactivities. Orbitides are a class of cyclic peptides
that are small, head-to-tail cyclized, composed of proteinogenic
amino acids and lack disulfide bonds; they are also known in
several genera of the plant family Rutaceae.Melicope xanthoxy-
loides is the Australian rain forest tree of the Rutaceae family in
which evolidine, the first plant cyclic peptide, was discovered.
Evolidine (cyclo-SFLPVNL) has subsequently been all but for-
gotten in the academic literature, so to redress this we used tan-
dem MS and de novo transcriptomics to rediscover evolidine
and decipher its biosynthetic origin from a short precursor just
48 residues in length. We also identified another six M. xan-
thoxyloides orbitides using the same techniques. These peptides
have atypically diverse C termini consisting of residues not
recognized by either of the known proteases plants use to mac-
rocyclize peptides, suggesting new cyclizing enzymes await dis-
covery. We examined the structure of two of the novel orbitides
by NMR, finding one had a definable structure, whereas the
other did not. Mining RNA-seq and whole genome sequencing
data from other species of the Rutaceae family revealed that
a large and diverse family of peptides is encoded by similar
sequences across the family and demonstrates how powerful de
novo transcriptomics can be at accelerating the discovery of new
peptide families.
Orbitides are a group of cyclic peptides found in plants. They
contain between five and 16 amino acid residues, are homo-
detic cycles, and have no disulfide bonds (1, 2). Orbitides are
thought to be ribosomally synthesized and post-translationally
modified peptides. Their genetic origins are known only for a
few groups: the segetalins of Vaccaria hispanica (3), some linu-
sorbs (previously cyclolinopeptides) from flax (Linum usitatis-
simum) (4), two curcacyclines from Jatropha curcas (1), a num-
ber of orbitides in Citrus species (3, 5), the annomuricatins of
Annona muricata (6) and the PawL-derived peptides (PLPs)
frommembers of the daisy family (Asteraceae) (7–9).
Evolidine is an orbitide from the leaves ofMelicope xanthox-
yloides (F. Muell.) T.G. Hartley (synonym Euodia xanthoxy-
loides F. Muell.), a species of the Rutaceae family, which is
found in the rainforest of northern Queensland in Australia,
the Lesser Sunda Islands, the Moluccas, Timor Leste, and New
Guinea (10–12). Evolidine was first isolated at the University of
Sydney, Australia, in 1952 (13), and its amino acid content and
cyclic nature were determined in 1955 (14). The amino acid
sequence was confirmed in 1961 (15) and the first synthesis of
the peptide was carried out in 1965 (16). A number of subse-
quent studies of the structure of evolidine have been carried
out, using both NMR (17, 18) and X-ray crystallography (Fig. 1)
(19). In 2005, evolidine was reported to have antibacterial and
antifungal activity (20).
Despite being the first cyclic peptide isolated from a plant,
evolidine has been overlooked by the natural product literature.
It was not included in the most comprehensive review of plant
cyclic peptides to date (21). Instead, perhaps because of the eco-
nomic importance of flaxseed, from which it comes, cyclolino-
peptide A is often cited as the first cyclic peptide (or sometimes
the first orbitide) discovered in a plant (1, 4, 21–25). However,
cyclolinopeptide A was not isolated until 1959 (26) and its
chemical structure solved only in 1966 (27).
We were interested in investigating the biosynthesis of evoli-
dine, the first plant cyclopeptide, and so we assembled a de
novo transcriptome for leaves of M. xanthoxyloides. We found
mRNA transcripts that encode evolidine and used MS to redis-
cover evolidine plus confirm six novel orbitides encoded by
similar transcripts. The C termini of these core peptides are
Phe, Lys, Leu, and Ser, none of which are residues recognized
by either of the known plant macrocyclizing enzymes, namely
asparaginyl endopeptidase (which recognizes Asp or Asn in the
P1 position) or prolyl oligopeptidase (which recognizes Pro or
Ala). Two of the novel orbitides were examined by NMR spec-
troscopy and their behavior varied in solution. Using the pre-
cursor sequences from M. xanthoxyloides, we analyzed RNA-
seq and whole genome sequencing (WGS) data from the
Sequence Read Archive (28) (SRA) and found genes and tran-
scripts encoding putative peptides in four genera from the Aur-
antioideae subfamily of the Rutaceae.
Results
We first confirmed the presence of evolidine in our tissue
sample by LC–MS. The peptide was sequenced by tandemMS
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(MS/MS) (Fig. S1). The observedm/z and lack of y ions showed
that the peptide was cyclic. To find the transcript that encodes
evolidine, we extracted total RNA from M. xanthoxyloides
leaves, performed RNA-seq, and assembled a transcriptome
using established methods (7). We searched the transcriptome
with tBLASTn for sequences encoding evolidine by using five
cyclic peptide precursor sequences from Citrus species (trans-
lated fromGenBank® accession numbers EF175924–EF175297
and FC872925); we reasoned that these could share sequence
similarity with the putative gene coding for evolidine because
both Melicope and Citrus belong to the Rutaceae family. We
found two sequences potentially coding for evolidine along
with;13 similar, putative peptide-encoding sequences. Align-
ing these sequences showed absolute conservation for the resi-
dues flanking evolidine (Glu and Ser), which indicated where
the peptide sequencemight lie.
Confirmation of further cyclic peptides by tandemMS and
Sanger sequencing
Having the sequences for transcripts encoding putative novel
cyclic peptides facilitated their identification and sequencing
from LC–MS/MS data. We found peaks corresponding to six
additional peptides of ;13 predicted by transcriptomic data
and sequenced the peptides by MS/MS (Table 1). We named
these peptides xanthoxycyclins A to F, and the corresponding
genes Proxanthoxyclins A to F (Fig. 2). The LC–MS data for
xanthoxycyclin A are shown in Fig. 3; data for xanthoxycyclins
B to F are shown in Fig. S3–S7.
The sequences of the core peptides lack conservation except
some at the N- and C-terminal residues. The N-terminal resi-
dues were ones with small side chains, namely Gly, Ser, and
Ala. The C-terminal residue was one of four possibilities: Phe
or Leu, Lys for xanthoxycyclin C, and Ser for xanthoxycyclin F.
In the sequence preceding the peptides, Glu is absolutely con-
served in the P1 position and the P2 residue is a highly-con-
served Ser, although for the two evolidine transcripts a Trp is
encoded. There are many other highly conserved residues,
especially in the sequence following the core peptide, where the
P1ʹ residue is always Ser and P2ʹ is most often Ile (Fig. 2). The
core peptides described above are typical orbitides in that they
contain mainly hydrophobic residues (1). With between six and
eight residues, they fall into the low-middle range of sizes for
orbitides, which can be as large as 16 amino acids (2).
We confirmed the sequences obtained by transcriptome as-
sembly and LC–MS/MS by designing primers against the ends
of each contig to amplify either genomic DNA, or a full-length
coding sequence using cDNA produced from poly-T-primed
RNA as the template. We were able to confirm one of the Proe-
volidine sequences (Fig. 4), and Proxanthoxycyclin E (Fig. S2A)
from genomic DNA. Proxanthoxycyclins B–D were sequenced
from cDNA and found to be a 100% match to the contigs
assembled by RNA-seq. It was not possible to Sanger sequence
Proxanthoxycyclin A due to the coding sequence being almost
identical to that of Proxanthoxycyclin B and the repetitive na-
ture of one of the regions to be primed. We were also unable to
PCR amplify the putative second Proevolidine gene or clone a
sequence for Proxanthoxycyclin F.
It is perhaps worth noting that when amplifying Proxanthox-
ycyclin E from genomic DNA template, as well as finding the
leaf peptide sequence we were searching for, we also amplified
six other sequences using the same primers (Fig. S2B). Five of
these were complete ORFs with a high degree of sequence simi-
larity to the Proxanthoxycyclins; another appeared to be a trun-
cated form. There was no evidence to support these in the leaf
MS/MS data, but these genes related to Proxanthoxycyclin
might not be expressed or could encode xanthoxycyclins that
are expressed in other tissues or specific growth stages not rep-
resented within the leaf sample we analyzed.
Potential peptide-encoding transcripts and genes in other
Rutaceae species
To investigate the prevalence of this kind of peptide-encod-
ing transcript within the Rutaceae, we searched the SRA to find
RNA-seq and WGS data for other species in the family. We
downloaded and assembled RNA-seq data from Aegle marme-
los fruit pulp, Atalantia buxifoliamature fruit, Bergera koenigii
leaf,Clausena excavata leaf, Zanthoxylum armatum young leaf
and Zanthoxylum bungeanum young leaf, as well as WGS data
for A. buxifolia and Clausena lansium. No peptide-encoding
transcripts were detected in either Zanthoxylum species, de-
spite their being closely related to Melicope and there being
three known orbitides in three different species in the genus
Zanthoxylum (29–31). Putative peptide-encoding transcripts
were found in all other RNA-seq datasets examined (Fig. 5),
which come from five species in four genera. All of these spe-
cies are in the Aurantioideae subfamily of the Rutaceae, to
whichCitrus also belongs.
Like those of M. xanthoxyloides, the potential propeptides
encoded within these five species also show a high sequence
similarity outside the core peptide sequence. Within the core
peptide, Gly is the most common residue at the N terminus,
but the C-terminal residues are even less conserved than the
core peptides of M. xanthoxyloides. In A. marmelos, Phe and
Leu are most common, as in M. xanthoxyloides, but the other
three species have a wide range of C-terminal residues, includ-








Figure 1. Structure of evolidine. Deposition number 1266027 at the Cam-
bridge Structural Database, obtained by X-ray crystallography (19).
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however, that there is no peptide evidence yet to indicate that
these encoded sequences are actually processed into orbitides,
so it would be unwise to speculate overly; indeed some sequen-
ces appear to encode cysteine residues that, to our knowledge,
have never been found in an orbitide. The high degree of con-
servation, with up to 50% identity and 60% similarity between
Table 1
Summary ofM. xanthoxyloides cyclic peptides, the genes that encode each and evidence for the peptides frommass spectrometry
The peptides are all backbone cyclic, with the sequences beginning with their proto-N terminus and ending with their proto-C terminus that are joined during
processing.
Peptide Sequence Gene(s) Peptide evidence
Evolidine SFLPVNL Proevolidine1, Proevolidine2 Eastwood et al. (14), Fig. S1
Xanthoxycyclin A GFAILF Proxanthoxycyclin A Fig. 4
Xanthoxycyclin B GFAILFF Proxanthoxycyclin B Fig. S3
Xanthoxycyclin C GYAPFPFK Proxanthoxycyclin C Fig. S4
Xanthoxycyclin D GTVAVQFL Proxanthoxycyclin D Fig. S5
Xanthoxycyclin E SSSPPIF Proxanthoxycyclin E Fig. S6
Xanthoxycyclin F AFVVPPRIS ProxanthoxycyclinF Fig. S7
MGT PC AGY TDWS E GG AP P WF- S L I ADD E I - NGN I D L L V V - PQYGRN PDH TG *
peptideCitrus clementina
FC872925 -
ME F S Y AGK I E LW S F L - P - VN S I H I - D E I AEDN L N L L V V - SQYGRN PD E SG *
ME F S Y AGK - - LW S F L - P - VN S I H I - D E I ADDN L N L L V - - SQYGRN PD E SG *
ME F S F AGKN E L S GF - A - - I L S F NQ I D EMADDN L N L I V V - PQYGRN YD E SG *
ME F S F AGEN E L S GF - A - I L F S F NQ I D E V ADDN L N L I V V - PQYGRN YD E SG *
ME F S F AGQN EQS GY - AP F P F S I H - DD E I GDDN L N L I A V - PQYGRN PN E SG *
ME F F F AGN I EQS GT V A - VQF S I H V - D E I ADDN L N L L V V L - QYGRN P - - - -
ME F F F AGK I E L S S S S - P P - I S F H I - D EMAHDN L N L L V V - PQYGRN PD E SG *

















Figure 2. M. xanthoxyloides peptide precursors aligned with a known Citrus orbitide precursor. The translated coding sequences for seven cyclic pep-

















m/zexp = 649.371 


































































































Figure 3. LC–MS/MS data for xanthoxycyclin A. A, extracted ion chromatogram atm/z 649.371. Inset left: mass spectrum at the chromatogram peak. Inset
right, cyclic peptide sequence with MS/MS ring cleavage point shown by an arrow, expected m/z (m/zexp) and observed m/z (m/zobs). B, MS/MS spectrum of
protonated molecule at m/z 649.371. A strong sequence of b ions is derived from initial ring opening between Leu and Phe residues. Immonium ions are la-
beledwith the corresponding amino acid residue.
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the flanking regions of the M. xanthoxyloides propeptides and
the Citrus clementina sequence FC872925, suggests that these
regions are important for peptide processing.
WGS data from the species A. buxifolia and C. lansium con-
tained many potential peptide-encoding sequences (Figs. S8
and S9, respectively), although it was not possible to say how
many might be expressed without transcriptomic data. One of
the sequences from C. lansium appeared to encode the known
peptide clausenlanin A (cyclo-GLILLLLLL) previously found in
that species (32). Another sequence potentially encoding a
peptide from C. lansium, clausenlanin B (cyclo-GLVLLLLLL)
(32), was found, but not in the data for that species; rather, it
was found in WGS data from A. buxifolia. The two putative
propeptide sequences show a remarkably high degree of con-
servation, differing only at three residues outside the core pep-
tide sequence (Fig. S10). The strong degree of sequence similar-
ity in the propeptides shown among the species studied here
and Citrus species investigated elsewhere (3, 5), especially in
the sequence following the core peptide, suggests a common
point of evolution for all these peptides across the Rutaceae.
NMR spectroscopy of synthetic xanthoxycyclins
Orbitides, due to their small size and restrained nature, con-
tain a limited variety of structural features. The majority of
orbitides are five to 10 residues with structural features being
limited to ordered loops (2), turns (33, 34), and mini-b-sheets
(35). Despite over 100 orbitides being discovered and reported
in CyBase (36), fewer than 10 3D structures have been solved
using either solution NMR spectroscopy or X-ray crystallogra-
phy and submitted to the Protein Data Bank (PDB) (36).
To explore the structural features of orbitides, we subjected
synthetic xanthoxycyclin D and xanthoxycyclin F to solution
NMR spectroscopy. The 1D NMR spectrum of xanthoxycyclin
D demonstrated sharp peaks with good signal dispersion in
H2O/D2O. A set of 2D NMR spectra, including TOCSY (total
correlation spectroscopy) (37) and NOESY (nuclear Over-
hauser effect spectroscopy) (38), were recorded and assigned
using a sequential assignment strategy. The NOESY spectrum
contained a large number of medium range NOEs (Table 2),
consistent with the peptide adopting an ordered structure.
Xanthoxycyclin D demonstrated relatively small deviations
from random coil Ha shifts (Fig. S11), however, deviations in
Ca and Cb chemical shifts (Fig. S11) allowed for prediction
of backbone dihedral angles by TALOS-N (torsion angle
likelihood obtained from shift and sequence similarity) (39)
for seven of the eight residues.
The dihedral angle restraints and NOE-based distance
restraints were used as input for simulated annealing and
energy minimization in explicit water, and resulted in a tightly
overlapping structural ensemble with a root mean square devi-
ation of 0.20 Å for the backbone atoms and 0.93 Å for all heavy
atoms (Fig. 6). Only one residue, Gln-6, appears to have
A G A T A G C T G A C G A C A A T C T T A A T C T G C T T G T A G T C T C T C A A T A T G G G A G A
A G A T A G C T G A C G A C A A T C T T A A T C T G C T T G T A G T C T C T C A A T A T G G G A G A
C A A A C T A T G G G A G T C T T T T C T T C C T G T C A A T C T T A G T A T T C A T A T T G A T G
C A A A C T A T G G G A G T C T T T T C T T C C T G T C A A T C T T A G T A T T C A T A T T G A T G
A A C C C T G A C G A A A G T G G C T A A
A A C C C T G A C G A A A G T G G T A AC
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A T G T A T G C G T G T T T G T T T A T G A G T A A C T T T T T C T T A A T G A C A A T T T C A G G
G
A T G G A A T T C T C T T A T G C A G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A T G G A A T T C T C T T A T G C A G G T A T T T T A C T A T T T C C A A A T G T T A T A G C A A A
-
Figure 4. Alignment of Proevolidine transcript and gene. The Sanger-sequenced gene data matches perfectly with the RNA-seq transcript, except that the
gene contains an 80-bp intron. The translated peptide sequence is shown between the nucleotide sequences; evolidine is shownwithin a box.
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ME T PR TGK K EW - - - - - - L E G A L I I L I L SMF DD E K I NNND L D L L S VPQ YGR Y L D Y T G *
ME S TC AG - N KW - - - - - - S E G VN I R PWH S I ADDD - N VSDN L DH L A VPQ YGRN PDN T G *
ME AS V AGEN KW - - - - - - S E G - - F F T L L A I I DD E V I YDN - L D L I V VPQ YGRN PD YSG *
ME S V F AGEN KWL E T P I I K E G L V - - T VQ S I VSD E - I GAD I L D L L V VPQQGRN PD E SG *
ME T PC TGKD EW - - - - - - S E C F P F L I F L G I VDN E K I NDDD L D L L V I PQ YGR YPD Y VG *
- E T PC TGKD EW - - - - - - S E C F L L F L F F G I VDN E K I NDGD L D L L V I PQ YGR YPD Y VG *
*
peptide
- - - - - - ME T P YPGKN EWC E GN P I - - T MY S I I N YEGVND - N L D L I V VPQYGRN L DH TG *
- - - - - - ME T TC AG - NMWS E G VN I - P PWH S I ADDDMVND - N L D L L V VPQYGRN PDRMG *
ME A V F AGKNQWL KMF VMK E G VP I WP YWD S I L VD E I T ND - N L D L L E VPQYGRN L N E TG *
- - - - - - ME T PC AD K SNWS E GH I L - D VR S S I ADDD A VNG - N L D F F V VPQHGR K PD Y TG *
- - - - - - ME T PC AGKN EWS E GK YS Y - - R P S I ADDD T AND - N L D F F V VPQHGR K PDH TG *
- - - - - - ME T TC AGNDDC L E GR P -W - N L A S I VDDN I AN A VN L D L L V F PQYGRN I DQ TG *
- - - - - - ME T PWAGKD EWL E GR PR K - - F S SML DD E E AN KDN L E L I V VPQNGRN PN Y TG *
*
peptide
ME T P - C TGQN EWS E G L L - - - C F C K I - DDD E S I NN KD L D F L V VPQYGRC PD Y TG *
ME T P - C TGKN EWS E G L L - - - F L C K I - DDD E S I NN KD L D F L V VPQYGRR PD Y TG *
ME T T ACRD KRDWS E A V L P P - F L L S I I ADD E - VMN EN L D L L I VPQYGRN L N Y L G *
ME T T T C TGKNDWS E G L P P P I Y F F S I A - DD E - I MNDN L D I L V VPQYGRN L N Y L G *
MG T P L A - G YNDWS E SNWT - I - H T SMT - DD - - I T NDN L D L L V VPQHGRN PD Y TG *
*
peptide
ME T I F TGN - KWS E G I - P - - F PR V S I A - EDD I MNDN L D F L V VPQYGRN PD YMG *
ME T I F TGK - KWS E G I - P - - ED L T SMA - DDD I MNDN L D F L V VPQYGRN PDHMG *
ME T I F TGN - KWS E G I L P - - - V A I S I A - DDD I MNDN L D F L V VPQYGRN PD YMG *
ME T I C AGN YDWS E T I I L L L F P L V S I L - DDD V TNDN L D L L V VPQYGR YPD Y T G *
ME T PC AGD - KWS E GL L I V L - L L L S V ADGE K VSDDN L N L L V VPQYGRN PD Y AG *
ME T PC SGKD EWS E GL ED - - - P LW S I A YD - E I FNDN L D L L V VPQYGRN L DR T G *
ME T SC AGNNNWT E NWGG - - - P F L G I V ADD E I ADH S L D F L MVPQYGRD PN Y T G *
ME T PC AGNNDWT E AWAG - - T N L V G I V ADD E I VDNN L D L L MVPQYGRD PN Y T G *
ME T T C AGK I DWS E CHRR PR - - RH S I - T DD E I EN EN L D L L V VPQYGR YPD Y T G *







Figure 5. Alignments of putative propeptide sequences from four Rutaceae species. Sequences are from (A) A. marmelos; (B) A. buxifolia, (C) B. koenigii,
and (D) C. excavata. Sequences are shown with background RasMol colors, and the putative peptide is marked and spaced from the surrounding sequence.
Asterisks represent stop codons. Below each alignment is the consensus sequence, the degree of conservation and a sequence logo.
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complete conformational freedom of its side chain. The side
chain of Phe-7 adopts two conformational states; these states
are reflected in the NMR data, which show a large chemical
shift separation of the two Hb protons but averaged 3JHaHb
coupling constants. The side chain of Leu-8 is locked into a sin-
gular conformation (gauche-trans); again reflected in the NMR
data, which shows a slightly weaker NH-Hb2 NOE compared
with the NH-Hb3 NOE and a large difference in 3JHaHb-cou-
pling constants, with the coupling between Ha and Hb2 being
significantly weaker than that between Ha andHb3 (40).
The structure of xanthoxycyclin D has two notable features.
First, a typical type III b-turn between residues Val-5 and Leu-
8. The type III turn is defined by a distance between the Ca car-
bons of Val-5 and Leu-8 (i and i1 3) of 4.5 Å, with the f and c
dihedral angles of Gln-6, 262°, 234° (i 1 1), and Phe-7, 260°,
231° (i 1 2), respectively. The turn is stabilized by a hydrogen
bond between the NH of Leu-8 and CO of Val-5. Second, an
atypical type III b-turn is formed between Thr-2 and Val-5.
Although the distance between the Ca carbons of Thr-2 and
Val-5, which is 5 Å, is consistent with a turn, and the f and c
dihedral angles of Val-3, 279°, 231° (i 1 1), and Ala-4, 279°,
239° (i 1 2) are similar to the common type III b-turn angles,
the hydrogen bond which stabilizes this turn is formed between
the HN of Val-5 and the side chain Og1 of Thr-2 rather
than the backbone carbonyl. Hydrogen bonds are also present
between Gly-1 HN–Gln-6 O and Thr-2 HN–Val-5 O. Addi-
tionally, the hydroxyl proton Hg1 of Thr-2 is within hydrogen
bond distance of the carbonyl of Val-5 in half of the models of
the structural ensemble. A weak resonance at 5.15 ppm was
indeed detected and assigned to Thr-2 Hg1 in the NMR data,
which is consistent with it being involved in a hydrogen bond.
However, this implies that there are three protons potentially
competing to form hydrogen bonds with the same carbonyl ox-
ygen, thus rearrangements allowing this sharing of acceptor
would likely be required.
Xanthoxycyclin F was also studied using solution NMR spec-
troscopy. In contrast to xanthoxycyclin D, the 1D spectrum
was of poor quality, and despite the appearance of a single pure
compound on HPLC analysis, the peptide adopted multiple
conformations in solution, evident from the numerous NMR
peaks observed. The 2D TOCSY and NOESY data confirmed
numerous conformations at almost every residue, presenting a
challenge for the assignment of the data. Despite this, a domi-
nant conformation was able to be assigned and confirmed using
a natural abundance 13C HSQC (heteronuclear single quantum
coherence spectroscopy). The secondary shifts of the dominant
confirmation were determined for all residues of xanthoxycy-
clin F (Fig. S12). It demonstrated secondary shifts that deviate
from random coil for most residues, but the complete lack of
any nonsequential NOEs, coupled with the complexity of sepa-
rating information from overlapping resonances from different
conformations, prevented sufficient data from being derived to
determine the structure of any of the conformers. A previous
study showed that somemembers of the PLP subfamily of orbi-
tides (PLPs-2, -4, -10, and -12) also demonstrate secondary Ha
shifts that deviate from random coil (8), indicating at least
some degree of ordered backbone, yet they displayed only irreg-
ular nonrigid structures lacking classical secondary structural
features.
Biological activities of M. xanthoxyloides orbitides
Poojary and Belagali (20) reported that evolidine inhibits the
growth of some bacteria and fungi. We attempted to replicate
these results and to extend the study to xanthoxycyclins D and
F, using disc diffusion assays like those in the prior work. Our
synthetic peptides were generated in house by solid phase pep-
tide synthesis or purchased so that we had enough material for
NMR structure determination and to test the antifungal and
antibacterial activity of the peptides. LC–MS/MS was used
to compare the properties of the natural and synthetic com-
pounds to verify that they were identical. The LC retention
times were compared and mirror plots of the MS/MS spectra
for each natural/synthetic pair were made. We concluded that
the natural and synthetic compounds were identical. This was
done for all three synthetic peptides: evolidine (Fig. S13), xan-
thoxycyclin D (Fig. S14), and xanthoxycyclin F (Fig. S15).
Our results showed no growth inhibition by any of the three
peptides against the Gram-negative bacterium Escherichia coli
K-12 nor against the Gram-positive bacterium Bacillus subtilis
Marburg No. 168, whereas a positive control disc containing 50
mg of kanamycin showed a clear zone of inhibition in every case
(Fig. S16). Similarly, the peptides were not active against either
Candida albicans or Aspergillus fumigatus (Fig. S17), although
a positive control disc containing 50 mg of amphotericin B
inhibited fungal growth. We attempted to use griseofulvin as a
positive control to follow the method of Poojary and Belagali,
Table 2












Clashes (.0.4 Å/1000 atoms) 0
Poor rotamers 0
Ramachandran outliers (%) 0
Ramachandran favored (%) 1006 0
MolProbity score 0.56 0
MolProbity score percentile 1006 0
Atomic root mean square deviations (Å)
Mean global backbone 0.206 0.06
Mean global heavy 0.936 0.24
Experimental restraints
Distance restraints
Short range (i-j, 2) 50
Medium range (/i-j/, 5) 24
Long range (/i-j/. 5) 0







Violations from experimental restraints
Total NOE violations exceeding 0.2 Å 0
Total dihedral violations exceeding 2.0° 0
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but found it had no effect on either fungal species, even with a
quantity four times that used in the earlier study (Fig. S18).
Discussion
Here we have shown that evolidine and six novel orbitides,
xanthoxycyclins A–F, in the leaves ofM. xanthoxyloides are ge-
netically encoded and we have solved the solution structure of
xanthoxycyclin D by NMR spectroscopy. Using public RNA-
seq andWGS data from the SRA, we have also identified similar
genes and transcripts in other plants from the Aurantioideae
subfamily of the Rutaceae, which may encode comparable
cyclic peptides, perhaps from a single evolutionary origin. Our
ability to discover all these sequences by searching with peptide
precursors from Citrus species points to a common ancestor
and orbitides made from precursors like these may be present
in many of the ;1,900 species of the Rutaceae (41). A study of
other species across this family could reveal more such orbiti-
des that might have interesting pharmacological properties.
Structure of xanthoxycyclin D
The 3D structure was determined using solution NMR spec-
troscopy. We showed that xanthoxycyclin D adopts a well-
defined structure in solution, comprising two distinct turns.
Although it is one residue longer than evolidine and with quite
a different sequence, the structures share some general features
that highlight the nature of the orbitide fold. Evolidine also
comprises two ordered b-turns involving residues Phe-2–Val-5
and Asn-6–Phe-2 (19). The conformation is stabilized by
hydrogen bonds involving both backbone and side chain atoms.
Evolidine-like xanthoxycyclin D contains a bifurcated hydrogen
bond in which the Phe-2 carbonyl serves as an acceptor for the
amide protons of both Val-5 and Asn-6. Both structures lack
substantial hydrophobic interactions, with the small ring size
resulting in the majority of side chains projecting away from
the core. Xanthoxycyclin F in contrast does not adopt a single
well-defined structure in solution, instead adopting multiple
conformations, as evident from a large number of additional
resonance signals. Thus, not all sequences are able to support a
single stable fold.
Bioactivity of evolidine
Our bioactivity results for evolidine were in contrast to the
prior work (20), which found that evolidine inhibited growth of
B. subtilis (strain not specified), and the fungi C. albicans and
Aspergillus niger using a similar assay to ours. The same study
was consistent with our finding that E. coli is unaffected by evo-
lidine. The prior study did not state what quantities of evolidine
were applied to the discs, preventing a direct comparison of the
results. This is not the first example of cyclic peptide bioactivity
being nonreproducible, although this occurred mostly when
synthetic compounds were compared with natural products.
This was previously observed in yunnanins A and C (orbitides
from Stellaria yunnanensis), where the synthetic compounds
had activity orders of magnitude lower than the natural prod-
ucts (42). The authors attributed this either to conformational
differences between the natural and synthetic products, or
traces of another compound in the natural extract. A similar
phenomenon has been seen for other, nonorbitide cyclic pep-
tides, such as phakellistatins 1 and 10 (42), phakellistatin 11
(43), and dolastatin 16 (44). This last case is intriguing, because
the study compared the synthetic product with natural samples
extracted and tested previously (45). The natural samples were
repurified using the samemethod applied to the synthetic com-
pound and their activity was found to be greatly reduced com-
pared with the earlier results (44, 45). This lends weight to the
hypothesis that trace impurities may be responsible for bioac-
tivities found only in natural extracts.
In our case, the compounds in our study and that of Poojary
and Belagali (20) were both synthetic, but differences in the
method of purification could account for the observed differen-
ces in activity. Poojary and Belagali (20) purified evolidine using
silica gel chromatography followed by recrystallization from
EtOAc–n-hexane, whereas we performed two rounds of re-
versed phase-HPLC (RP-HPLC). In addition, the earlier study
used griseofulvin as a positive control against C. albicans,
Figure 6. NMR solution structure of xanthoxycyclin D. Left image is of the structural ensemble of 20 best structures superimposed, shown in stick format.
Right image is a single structure of xanthoxycyclin D in stick format illustrating hydrogen bonding with dashed lines. Hydrogen bond donors are shown in
cyan, with hydrogen bond acceptors being shown inmagenta. Both left and right images show the peptide backbone in blue, hydrophobic side chains in green
and polar side chains in red.
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although it has long been known to be ineffective against Can-
dida species (46). Although our results showed no biological
activity for evolidine or the two other xanthoxycyclins tested,
previous work on orbitides in the Citrus genus has suggested
that such peptides might act as potassium ionophores in plant
phloem (5).
Biosynthesis of M. xanthoxyloides orbitides
Several studies have investigated the post-translational proc-
essing required tomature plant cyclic peptides. Asparaginyl en-
dopeptidase, a protease that recognizes Asp or Asn at the C ter-
minus of the core peptide for cleavage, has also been recruited
by evolution multiple times to perform cyclization of different
cyclic peptide families via a transpeptidation reaction. These
include (i) kalata-type cyclic peptides (cyclotides), a family of
plant macrocyclic peptides containing three disulfide bonds
(47–49); (ii) the cyclic knottins, a family of mostly trypsin-in-
hibitory peptides from the squash family (48, 50); and (iii) the
single-disulfide PawS-derived peptides of the daisy family (51)
and presumably the closely-related PawL-derived peptides, a
group of orbitides in the daisy family with an absolutely con-
served Asp at the C terminus of the core peptide (7, 8).
Previous work has revealed that a second cyclization mecha-
nism in plants involving a prolyl oligopeptidase named peptide
cyclase 1 (PCY1) is responsible for cyclization of the segetalin
orbitides in Vaccaria hispanica (Saponaria vaccaria) (3, 23).
This enzyme recognizes Pro, or sometimes Ala, at the C termi-
nus of the core peptide. It is likely that a prolyl oligopeptidase is
similarly responsible for cyclizing the annomuricatin orbitides
in A. muricata, which all have Pro or Ala in an equivalent posi-
tion (6).
The xanthoxycyclins of M. xanthoxyloides differ from both
the above groups because their core peptide sequences termi-
nate with Phe, Leu, Ser, or Lys. None of these four residues are
recognized by the aforementioned asparaginyl endopeptidase
(Asn/Asp) or prolyl oligopeptidase (Pro/Ala). If xanthoxycy-
clins are matured by proteases performing a similar cleavage-
coupled intra-molecular transpeptidation with the C-terminal
residue, our confirmation of these orbitide sequences indicates
one or more novel cyclization mechanisms are yet to be discov-
ered in this species, perhaps involving a different class of prote-
ase. We would consider the next step to be to attempt to purify
this cyclizing enzyme from fractioned plant extracts, by follow-
ing the desired cyclizing activity.
Here we hope we have redressed priority to evolidine as
being the first plant cyclopeptide to be discovered and, by
revealing the biosynthetic precursor gene for evolidine and its
relatives in the Rutaceae, are able to propose that a novel type
of cyclizing enzyme exists in plants awaiting discovery.
Experimental procedures
Plant material
Leaves and stems of M. xanthoxyloides were collected on 13
June 2019, by S. Venter (reference 15917) from Smithfield Con-
servation Park, Queensland, Australia (16.80609° S, 145.67583°
E) under permit PTU18-001474. A voucher specimen has been
deposited in the Australian Tropical Herbarium. After remov-
ing the stems, the leaves were ground to a powder under liquid
nitrogen and stored at270 °C.
Synthetic peptides
Evolidine was synthesized using solid phase peptide synthesis
on an automated peptide synthesiser (CS Bio Pty. Ltd.) using
fluorenylmethyloxycarbonyl (Fmoc) chemistry on 2-chlorotri-
tyl resin (0.25 mmol scale). Loading of the C-terminal Leu resi-
due (1 molar eq.) was achieved by dissolving the Fmoc-pro-
tected Leu residue in dichloromethane, adding 4 molar eq ofN,
Nʹ-diisopropylethylamine (DIPEA) to the dissolved residue
and adding this to the resin. Subsequent amino acids (4 eq.)
were activated in 0.5 M 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate and DIPEA (8 eq.) in N,
N’-dimethylformamide. The coupling reaction was performed
twice for amino acids containing branched b-carbons or aro-
matic rings. The peptide was cleaved from the resin whilst
maintaining attachment of sidechain protecting groups using
2% TFA (v/v) in dichloromethane for 3 min. This was repeated
10 times. Acetonitrile was added to the peptide solution and
dichloromethane and TFA were removed via rotary-evapora-
tion and the peptide portion lyophilized. The peptide was then
cyclized in dimethylformamide; this was done by adding 1-[bis
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridin-
ium 3-oxide hexafluorophosphate (1 eq.) to a 1 mM peptide so-
lution, followed by the slow addition of DIPEA (10 eq.). The
reaction was monitored by electrospray ionizationMS over 3 h.
The peptide was then extracted from the dimethylformamide
using phase extraction, prior to lyophilization. The remaining
side chain protecting groups were cleaved using TFA/water/
triisopropylsilane (97:2:1) for 2 h, the peptide was precipitated
with cold diethyl ether, filtered, and dissolved in 50% acetoni-
trile before lyophilization. The crude peptide was purified with
RP-HPLC on a C18 preparative column (300 Å, 10 mm, 21.20
mm internal diameter 3 250 mm, Phenomenex). Electrospray
ionization MS was used to confirm the mass of evolidine, with
further purifications being conducted on a semi-preparative
C18 column (300 Å, 5 mm, 10 mm internal diameter 3 250
mm, Vydac) with purity being assessed with a C18 analytical
column (300 Å, 5 mm, 2.1 mm internal diameter 3 150 mm,
Vydac). Xanthoxycyclin D and xanthoxycyclin F were pur-
chased from GenScript Inc. (Piscataway, NJ). The purity of all
peptides was assessed by RP-HPLC with a C18 analytical col-
umn (300 Å, 5 mm, 2.1 mm internal diameter 3 150 mm,
Vydac) and confirmed to be95%.
Peptide extraction and purification
Peptides were extracted from plants as described previously
(7). Briefly, about 1 g of leaf powder was ground with 50 ml of
50% methanol, 50% dichloromethane (v/v). The extract was
dried with anhydrous magnesium sulfate and filtered under a
vacuum with two 50-ml washes of solvent. After flash chroma-
tography though silica gel, the samples were dried in a rotary
evaporator (Heidolph). These leaf peptide extracts were then
purified as previously described (8). Briefly, the crude extract
was purified by solid-phase extraction using a 30-mg Strata-X
polymeric reversed-phase column (Phenomenex). The dried
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extract was dissolved in 2 ml of an aqueous solution of 5% ace-
tonitrile (v/v), 0.1% formic acid (v/v) and dispensed onto the
column, after which purified peptides were eluted with 75%
acetonitrile (v/v), 0.1% formic acid (v/v). The purified extract
was desiccated in a vacuum centrifuge (Labconco) and then
prepared for LC–MS analysis by redissolving it in 50 ml of
HPLC-grade 5% acetonitrile (v/v), 0.1% formic acid (v/v)
(Honeywell).
LC–MS/MS for peptide sequencing
Samples (2 ml) were separated by a gradient elution from 5%
solvent B to 95% solvent B over 15 min on a high-capacity
nano-LC chip (Agilent Technologies; part number G4240-
62010) driven by a 1200 series nano-flow HPLC system (Agi-
lent) at a flow rate of 300 nl/min. Solvent A was 0.1% (v/v) for-
mic acid in water and solvent B was 0.1% (v/v) formic acid in
acetonitrile. Both solvents were HPLC-grade (Honeywell). Pep-
tides were detected with either a 6520 or 6550 Q-TOF mass
spectrometer (Agilent) via electrospray ionization in positive
mode with one MS scan per second. The source voltage was set
between 2100 and 2175 V. MS/MS data were gathered by colli-
sion-induced dissociation at a rate of two scans per second,
with the expected peptidem/z values set as “preferred” for frag-
mentation. Visual inspection of MS/MS data were used to
sequence the cyclic peptides, guided by transcriptomic data for
the six novel peptides, and the known sequence for evolidine.
RNA-seq and transcriptome assembly
Total RNA was isolated from frozen ground leaf tissue ofM.
xanthoxyloides using the mini hot phenol method (52), which
in turn is derived from the protocol of Botella et al. (53). Total
RNA was treated with DNase and subsequently purified with
the NucleoSpin RNA Clean-Up kit (Macherey-Nagel). It was
validated by both agarose gel electrophoresis and absorbance
measurement on a NanoDrop2000 (Thermo Fisher Scientific).
RNA-seq libraries were generated using the TruSeq Stranded
Total RNA with Ribo-Zero Plant kit according to the manufac-
turer’s instructions (Illumina) and sequenced on a NextSeq 550
system (Illumina) as single end reads with a length of 75 bp.
The data set contained 9.7 3 109 raw reads and 95% of reads
had an average quality score at or above Q30. The leaf tran-
scriptome was assembled using CLC Genomics Workbench
12.0.2 (Qiagen Aarhus A/S). The raw reads were trimmed to a
quality threshold of Q30 and minimum length 15, and assem-
blies were performed with word sizes 23, 30, 40, 50, and 64 and
minimum contig length 200. Other parameters remained at
their default values.
Analysis of data from the sequence read archive
We searched the SRA for RNA-seq and WGS data for other
species in the Rutaceae family. Using CLC Genomics Work-
bench, RNA-seq data from A. marmelos fruit pulp (SRA run
SRR8190707),A. buxifoliamature fruit (SRR6349678),B. koeni-
gii leaf (SRR2970920); C. excavata leaf (SRR 6438389), Z. arma-
tum young leaf (SRR9179743) and Z. bungeanum young leaf
(SRR9179746), and WGS data for A. buxifolia (SRR6188460)
and C. lansium (SRR5796634) were downloaded. Data were
assembled to a quality threshold Q30 and minimum contig
length 100; other parameters were set to their default values,
including word size, which the software determined automati-
cally. The assembled transcriptomic and genomic data were
subjected to tBLASTn searches using the evolidine and xan-
thoxycyclin propeptide sequences to find highly similar sequen-
ces. Themaximum expected value for search results was set to 1
and BLOSUM45was used as the substitution database.
Extraction of genomic DNA
Genomic DNA (gDNA) was extracted from 2 g of frozen
ground powder of M. xanthoxyloides leaves with the DNEasy
Plant Mini Kit (Qiagen) according to the manufacturer’s
instructions. Purified DNAwas quantified on a NanoDrop 2000
(Thermo Fisher Scientific).
First strand cDNA synthesis
Complementary DNA (cDNA) was generated from previ-
ously extracted total RNA (900 ng) using the SMARTER RACE
59/39 kit (Takara Bio USA) according to the manufacturer’s
instructions. A poly-T primer was used. The 20-ml reaction was
diluted to 110ml with water.
PCR and cloning of propeptide genes and transcripts
TheDNA template was amplified by the PCR using Pfu high-
fidelity DNA polymerase (Agilent Technologies). Each 50-ml
reaction consisted of gDNA (;27 ng) or cDNA (1 ml) and 1
unit of Pfu DNA polymerase solution, with MgCl2 to a final
concentration of 2 mM, 400 mM mixed dNTPs, 10 mM KCl, 10
mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 0.1 mg/ml of BSA,
0.1% Triton X-100, and forward and reverse primers, 0.4 mM
(Table S1).
PCR amplification was carried out in a Veriti 96-well ther-
mocycler (Applied Biosystems) programmed as follows: 95 °C
for 2 min followed by 35 cycles of 95 °C for 30 s; 55 °C for 30 s;
72 °C for 30 s; and finally 72 °C for 10 min. In some cases it was
necessary to repeat the PCR a second time using 2 ml of the ini-
tial PCR product to produce sufficient DNA for subsequent
reactions. PCR products were purified using theQIAquick PCR
Purification Kit (Qiagen) according to the manufacturer’s
instructions. DNA was eluted in 30 ml of water after allowing
incubation on the column membrane for 1 min, and quantified
on a NanoDrop 2000. The Proxanthoxycyclin D cDNA was
Sanger sequenced directly from the PCR product using the
same primers as the PCR (Table S1).
The other products were cloned as follows: overhanging
adenosine bases were added to PCR products in an “A-tailing”
reaction using Taq DNA polymerase. Each 20-ml reaction con-
sisted of;150 ng of PCR product, 1 unit of TaqDNA polymer-
ase, dNTPs to a final concentration of 400 mM, 2 mM MgCl2, 20
mM Tris-HCl (pH 8.8), and 50 mM KCl. Reactions were incu-
bated at 37 °C for 20min.
Either;12.5 ng (Proxanthoxycyclin C cDNA),;25 ng (Prox-
anthoxycyclin B cDNA), or ;30 ng (Proevolidine and Proxan-
thoxycyclin E gDNA) of the A-tailed PCR product were ligated
into 50 ng of the pGEM-T Easy vector (Promega) according to
the manufacturer’s instructions. Each reaction was incubated
Genetic origin of the evolidine cyclopeptide family
14518 J. Biol. Chem. (2020) 295(42) 14510–14521
overnight at 4 °C. LB agar plates were prepared containing 100
mg/ml of ampicillin and 100 mM of isopropyl b-D-1-thiogalacto-
pyranoside. Plates were spread with 20 ml of 50 mg/ml 5-
bromo-4-chloro-3-indolyl-b-D-galactoside, which was allowed
to be absorbed for at least 30 min. These plates were inoculated
with a culture of TOP10 E. coli cells transformed with 2 ml of
the ligated vector and incubated overnight at 37 °C. Aliquots of
LB (5ml) were each inoculated with a single colony from a plate
and incubated overnight at 37 °C with shaking.
Plasmid DNA was extracted with the GeneJET PlasmidMin-
iprep Kit (Thermo Fisher Scientific) according to the manufac-
turer’s instructions. DNA was eluted in 50 ml of water and sent
for dideoxy sequencing using the M13F primer of the pGEM-T
Easy vector (Australian Genome Research Facility, Perth).
NMR spectroscopy
Xanthoxycyclin samples were prepared by dissolving 2 mg of
peptide in 550 ml of H2O/D2O (90:10) at pH;3.5. One-dimen-
sional 1H data, homonuclear 1H-1H two-dimensional TOCSY
(37), NOESY (38), and DQF-COSY (double quantum filtered-
correlated spectroscopy) experiments were recorded at 298 K
on a 900MHz Bruker Avance III spectrometer equipped with a
cryoprobe. TOCSY experiments were recorded with 8 scans
and 512 increments and two NOESY experiments were
recorded with 48 scans and 512 increments with mixing times
of 100 and 200 ms. Sweep widths of 10 ppm were sufficient to
cover all proton resonances. Additionally, a 1H-13C HSQC
spectrum was recorded at natural abundance using 128 scans
and 256 increments with a sweep width of 10 ppm in the F2
direct dimension and 80 ppm in the F1 dimension. All data
were processed using Topspin 4.0.3 (Bruker), with the solvent
signal referenced to 4.77 ppm at 298 K. The spectra were ana-
lyzed and assigned with the program CARA (computer aided
resonance assignment) (54) using sequential assignment strat-
egies (55). Observed Ha, Ca, and Cb shifts were determined
and compared with random coil values (56) for all residues to
generate secondary shift graphs. Additionally, amide proton
temperature dependence was determined by recording TOCSY
data at varying temperatures (288, 293, 298, 303, and 308 K).
The chemical shift of each HN proton was plotted against tem-
perature to determine the temperature coefficients.
Solution structure calculations
Integrated peak volumes from NOESY data were used to
determine inter-proton distance restraints for xanthoxycyclin
D. TALOS-N (39) was used to predict the f (C21-N-Ca-C)
and c (N-Ca-C-N11) backbone dihedral angles. Hydrogen
bond donors were identified by backbone amide temperature
coefficients. Values 4.6 ppb/K for the coefficient are indica-
tive of hydrogen bond donation (57); hydrogen bond acceptors
were identified from preliminary structure calculations (57).
Preliminary structures (50) were calculated using torsion angle
simulated annealing in CYANA (combined assignment and dy-
namics algorithm for NMR applications) (58). The results of
these calculations defined the starting coordinates and distance
restraints used for refinement in the program CNS (crystallog-
raphy and NMR system) (59). NOE distances, dihedral
restraints from TALOS-N, and hydrogen bond restraints were
all used as input for CNS. Simulated annealing using torsion
angle dynamics was performed in CNS to generate 50 struc-
tures. All 50 structures were then further minimized in water
usingCartesian dynamics to generate the final structures of xan-
thoxycyclin D. MolProbity (60) was used for stereochemical
analysis of the structures via comparison to previously pub-
lished structures in the PDB. Images of the structure of the xan-
thoxycyclin D were generated by the program MOLMOL (61).
The best 20 structures based on good geometry, no violations
above 0.2 Å or 2°, and low energy were chosen to represent the
solution structure of xanthoxycyclin D.
Antibacterial and antifungal disc diffusion assays
Synthetic peptides were dissolved in DMSO to a concentra-
tion of either 20 mg/ml (evolidine) or 50 mg/ml (xanthoxycy-
clins D and F). Antibacterial assays were carried out by a previ-
ously described method (8). Briefly, sterile LB agar plates were
prepared and evenly inoculated with cultures of E. coli K-12 or
B. subtilis Marburg No. 165 using a sterile swab. The cultures
had been prepared in liquid LB medium and diluted to an opti-
cal density at 600 nm (A600) of 0.1. We also prepared sterile 8-
mm filter paper discs containing either a positive control (50 mg
of kanamycin), negative control (5 ml of sterile water), or one of
the three peptides. Six discs contained 200, 100, 50, 25, 10, or 5
mg of evolidine or 200, 100, 50, 25, 12.5 or 5 mg of xanthoxycy-
clin D or F. The discs were placed onto the six bacterial plates,
incubated overnight at 37 °C, and then inspected for any inhibi-
tion bacterial growth by the discs.
A similar but simplified disc diffusion assay was carried out
against two species of fungi: A. fumigatus and C. albicans. A
glycerol stock of each species was streaked onto a sterile yeast
extract, peptone and dextrose (YPD) agar plate. Cultures were
incubated at 37 °C for;48 h before spores were harvested with
3 ml of sterile 0.1% Tween 80. The spore suspensions were then
diluted to an A600 of 0.05 and spread onto fresh YPD plates
with a sterile swab. Control discs of sterile 8-mm filter paper
were prepared with 50 mg of amphotericin B (positive control)
or 5 ml of DMSO (negative control). Another three discs con-
tained 200 mg of each peptide. A set of discs was placed onto
each of the two fungal plates and incubated for ;24 h at 37 °C
before inspection for any inhibition of fungal growth.
Data availability
The M. xanthoxyloides RNA-seq raw reads were deposited
in the SRA under BioProject accession number PRJNA561449.
The seven evolidine- and proxanthoxycyclin-encoding genes or
transcripts from this study were deposited in GenBank under
accession numbers MN655996 and MT473297. The structure
of xanthoxycyclin D was submitted to the PDB under the iden-
tifier 6WPV and to the Biological Magnetic Resonance Bank
(30747) MS data were deposited to the EMBL-EBI Metabo-
Lights database (62) with the identifierMTBLS1963.
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